Dr. Daver Compares Toxicity Profiles of TKIs in CML
August 29th 2019
Naval G. Daver, MD, associate professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses safety differences between the TKIs ponatinib, dasatinib (Sprycel) and nilotinib (Tasigna) in the treatment of patients with chronic myeloid leukemia.